Overview

A Study of LAM-003 in Patients With Acute Myeloid Leukemia

Status:
Unknown status
Trial end date:
2020-01-01
Target enrollment:
Participant gender:
Summary
A Phase 1 Dose-Escalation Study of LAM-003 in Patients with Acute Myeloid Leukemia
Phase:
Phase 1
Details
Lead Sponsor:
AI Therapeutics, Inc.
Lam Therapeutics Inc.